Peptit Yy’nin Temel Ve Klinik Özellikleri

Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al., Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology. 1985;89:1070–1077.

De Silva A, Bloom SR. Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity. Gut Liver. 2012;6(1):10-20. doi: 10.5009/gnl.2012.6.1.10. Epub 2012 Jan 12.

Tatemoto K. Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci U S A. 1982;79(8):2514-8. doi: 10.1073/pnas.79.8.2514.

Huang Y, Lin X, Lin S. Neuropeptide Y and Metabolism Syndrome: An Update on Perspectives of Clinical Therapeutic Intervention Strategies. Front Cell Dev Biol. 2021;9:695623. doi: 10.3389/fcell.2021.695623.

Holzer P, Reichmann F, Farzi A. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides. 2012 ;46(6):261-74. doi: 10.1016/j.npep.2012.08.005.

Batterham RL, Bloom SR. The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci. 2003;994:162-8. doi: 10.1111/j.1749-6632.2003.tb03176.x.

Pedragosa-Badia X, Stichel J, Beck-Sickinger AG. Neuropeptide Y receptors: how to get subtype selectivity. Front Endocrinol (Lausanne). 2013;4:5. doi: 10.3389/fendo.2013.00005.

Cabrele C, Beck-Sickinger AG. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. J Pept Sci. 2000;6(3):97-122. doi: 10.1002/(SICI)1099-1387(200003)6:3<97::AID-PSC236>3.0.CO;2-E.

9.Reidelberger R, Haver A, Chelikani PK. Role of peptide YY(3-36) in the satiety produced by gastric delivery of macronutrients in rats. Am J Physiol Endocrinol Metab. 2013;304(9):E944-50. doi: 10.1152/ajpendo.00075.2013.

Batterham RL, Heffron H, Kapoor S, et al., Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab. 2006;4(3):223-33. doi: 10.1016/j.cmet.2006.08.001.

Adamska E, Ostrowska L, Górska M, et al., The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes. Prz Gastroenterol. 2014;9(2):69-76. doi: 10.5114/pg.2014.42498.

Troke R, Tan TM, Bloom SR. PYY. Handbook of Biologically Active Peptides (Second Edition), 2013. p.1160-1165.

Farzi A, Ip CK, Reed F, Enriquez R, et al., Lack of peptide YY signaling in mice disturbs gut microbiome composition in response to high-fat diet. FASEB J. 2021;35(4):e21435. doi: 10.1096/fj.202002215R.

Chelikani PK. Does PYY mediate resolution of diabetes following bariatric surgery? EBioMedicine. 2019;40:5-6. doi: 10.1016/j.ebiom.2019.01.034.

Camilleri M. Gastrointestinal hormones and regulation of gastric emptying. Curr Opin Endocrinol Diabetes Obes. 2019;26(1):3-10. doi: 10.1097/MED.0000000000000448.

Whang EE, Hines OJ, Reeve JR Jr, et al., Antisecretory mechanisms of peptide YY in rat distal colon. Dig Dis Sci. 1997;42(6):1121-7. doi: 10.1023/a:1018869116284.

Vona-Davis L, McFadden DW. PYY and the pancreas: inhibition of tumor growth and inflammation. Peptides. 2007;28(2):334-8. doi: 10.1016/j.peptides.2006.07.033.

El-Salhy M, Mazzawi T, Gundersen D, et al., The role of peptide YY in gastrointestinal diseases and disorders (review). Int J Mol Med. 2013;31(2):275-82. doi: 10.3892/ijmm.2012.1222.

Nishizawa N, Niida A, Masuda Y, et al., A Short-Length Peptide YY Analogue with Anorectic Effect in Mice. ACS Omega. 2017;2(5):2200-2207. doi: 10.1021/acsomega.7b00258.

Tan TM, Minnion J, Khoo B, et al., Safety and efficacy of an extended-release peptide YY analogue for obesity: A randomized, placebo-controlled, phase 1 trial. Diabetes Obes Metab. 2021;23(7):1471-1483. doi: 10.1111/dom.14358.

Mishima Y, Ishihara S. Molecular Mechanisms of Microbiota-Mediated Pathology in Irritable Bowel Syndrome. Int J Mol Sci. 2020;21(22):8664. doi: 10.3390/ijms21228664. PMID: 33212919; PMCID: PMC7698457.

Ballantyne GH. Peptide YY (1–36) and peptide YY (3–36): Part I. Distribution, release and actions. Obes Surg. 2006;16:651–658.

Stasi C, Bellini M, Gambaccini D, et al. Neuroendocrine dysregulation in irritable bowel syndrome patients: a pilot study. J Neurogastroenterol Motil 2017; 23: 428–434.

Simren M, Stotzer PO, Sjovall H, et al. Abnormal levels of neuropeptide Y and peptide YY in the colon in irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2003; 15: 55–62.

El-Salhy M, Gilja OH, Gundersen D, Hatlebakk JG, Hausken T. Endocrine cells in the ileum of patients with irritable bowel syndrome. World J Gastroenterol. 2014;20(9):2383-91. doi: 10.3748/wjg.v20.i9.2383. PMID: 24605036; PMCID: PMC3942842.

El-Salhy M, Gilja OH. Abnormalities in ileal stem, neurogenin 3, and enteroendocrine cells in patients with irritable bowel syndrome. BMC Gastroenterol. 2017;17(1):90. doi: 10.1186/s12876-017-0643-4. PMID: 28764761; PMCID: PMC5539900.

Mazzawi T, Hausken T, Gundersen D, et al., Dietary guidance normalizes large intestinal endocrine cell densities in patients with irritable bowel syndrome. Eur J Clin Nutr. 2016;70(2):175-81. doi: 10.1038/ejcn.2015.191.

Lundin KE, Wijmenga C. Coeliac disease and autoimmune disease-genetic overlap and screening. Nat Rev Gastroenterol Hepatol. 2015;12(9):507-15. doi: 10.1038/nrgastro.2015.136.

Wahab PJ, Hopman WP, Jansen JB. Basal and Fat-Stimulated Plasma Peptide YY Levels in Celiac Disease. Dig. Dis. Sci. 2001;46:2504–2509. doi: 10.1023/A:1012344424300.

Hoentjen F, Hopman WP, Jansen JB. Effect of Circulating Peptide YY on Gallbladder Emptying in Humans. Scand. J. Gastroenterol. 2001;36:1086–1091. doi: 10.1080/003655201750422710.

Poddighe D, Dossybayeva K, Abdukhakimova D, et al., Celiac Disease and Gallbladder: Pathophysiological Aspects and Clinical Issues. Nutrients. 2022;14(20):4379. doi: 10.3390/nu14204379.

Bottani M, Cattaneo S, Pica V, Set al., Gastrointestinal In Vitro Digests of Infant Biscuits Formulated with Bovine Milk Proteins Positively Affect In Vitro Differentiation of Human Osteoblast-Like Cells. Foods. 2020;9(10):1510. doi: 10.3390/foods9101510.

Sjölund K, Ekman R. Increased plasma levels of peptide YY in coeliac disease. Scand J Gastroenterol. 1988;23(3):297-300. doi: 10.3109/00365528809093868. PMID: 3387893.

El-Salhy M, Suhr O, Danielsson A. Peptide YY in gastrointestinal disorders. Peptides. 2002;23(2):397-402. doi: 10.1016/s0196-9781(01)00617-9.

El-Salhy M: The possible role of the gut neuroendocrine system in diabetes gastroenteropathy. Histol Histopathol. 2002;17:1153–1161.

El-Salhy M and Sitohy B: Abnormal gastrointestinal endocrine cells in patients with diabetes type 1: relationship to gastric emptying and myoelectrical activity. Scand J Gastroenterol. 2001;36:1162–1169..

El-Salhy M: Neuroendocrine peptides in stomach and colon of an animal model for human diabetes type 1. J Diabetes Complications. 1999;13:170–173.

El-Salhy M: Neuroendocrine peptides of the gastrointestinal tract of an animal model of human type 2 diabetes mellitus. Acta Diabetol. 1998;35:194–198.

Portela-Gomes GM, Wilander E, Grimelius L, et al., The enterochromaffin cells in the mouse gastrointestinal tract after streptozotocin treatment. Pathol Res Pract.1990; 186:260–264.

Grise KR, McFadden DW. Peptide YY improves local and systemic parameters and prevents death in lethal necrotizing pancreatitis. Pancreas. 2002;24(1):90-5. doi: 10.1097/00006676-200201000-00012.

Kazanjian KK, Towfigh S, McFadden DW. Peptide YY exhibits a mitogenic effect on pancreatic cells while improving acute pancreatitis in vitro J Surg Res, 2003; 11495-99.

Robinson K, Vona-Davis L, Riggs D, et al., Peptide YY attenuates STAT1 and STAT3 activation induced by TNF-alpha in acinar cell line AR42J. J Am Coll Surg. 2006;202(5):788-96. doi: 10.1016/j.jamcollsurg.2006.01.007.

Robinson KS, Vona-Davis L, Riggs D, Jackson B, McFadden DW. Peptide YY attentuates STAT1 and STAT3 activation induced by TNF-alpha in acinar cell line AR42J. J Am Coll Surg, 2006; 202:788-796.

Zygulska AL, Furgala A, Kaszuba-Zwoińska J, et al., Changes in plasma levels of cholecystokinin, neurotensin, VIP and PYY in gastric and colorectal cancer - Preliminary results. Peptides. 2019;122:170148. doi: 10.1016/j.peptides.2019.170148.

Choi YY, Noh SH, An JY. A randomized controlled trial of Roux-en-Y gastrojejunostomy vs. gastroduodenostomy with respect to the improvement of type 2 diabetes mellitus after distal gastrectomy in gastric cancer patients. PLoS One. 2017;12(12):e0188904. doi: 10.1371/journal.pone.0188904.

Jeon TY, Lee S, Kim HH, et al., Long-term changes in gut hormones, appetite and food intake 1 year after subtotal gastrectomy with normal body weight. Eur J Clin Nutr. 2010;64(8):826-31. doi: 10.1038/ejcn.2010.83.

Nehlsen AD, Goodman KA. Controversies in radiotherapy for pancreas cancer. J Surg Oncol. 2021;123(6):1460-1466. doi: 10.1002/jso.26313.

Li H, Wang Z, Dong L, et al., Peptide tyrosine-tyrosine combined with its receptors exhibits an anti-cancer potential in pancreatic cancer MiaPaCa-2 cell. Chin Med J (Engl). 2014;127(24):4235-42. PMID: 25533827.

Liu CD, Rongione AJ, Garvey L, et al., Adjuvant hormonal treatment with peptide YY or its analog decreases human pancreatic carcinoma growth. Am J Surg. 1996;171(1):192-6. doi: 10.1016/S0002-9610(99)80098-1.

Liu CD, Kwan D, Simon N, et al., Synthetic peptide YY analog binds to a cell membrane receptor and delivers fluorescent dye to pancreatic cancer cells. J Gastrointest Surg. 2001;5(2):147-52. doi: 10.1016/s1091-255x(01)80026-3.

Thanikachalam K, Khan G. Colorectal Cancer and Nutrition. Nutrients. 2019;11(1):164. doi: 10.3390/nu11010164. PMID: 30646512; PMCID: PMC6357054.

Jing F, Liu G, Zhang R, et al., PYY modulates the tumorigenesis and progression of colorectal cancer unveiled by proteomics. Am J Cancer Res. 2022;12(12):5500-5515.

Calam J, Ghatei MA, Domin J, et al., Regional differences in concentrations of regulatory peptides in human colon mucosal biopsy. Dig Dis Sci. 1989; 34(8):1193-8. doi: 10.1007/BF01537267.

Adrian TE, Ballantyne GH, Zucker KA, et al.,. Lack of peptide YY immunoreactivity in adenomatous colonic polyps: evidence in favor of an adenoma-carcinoma sequence. J Surg Res. 1988;44(5):561-5. doi: 10.1016/0022-4804(88)90162-x.

Gomez G, Zhang T, Rajaraman S, et al., Intestinal peptide YY: ontogeny of gene expression in rat bowel and trophic actions on rat and mouse bowel. Am J Physiol. 1995;268 (1 Pt 1):G71-81. doi: 10.1152/ajpgi.1995.268.1.G71.

Sandström O, Mahdavi J, El-Salhy M. Effect of ageing on colonic endocrine cell population in mouse. Gerontology. 1998;44(6):324-30. doi: 10.1159/000022036. PMID: 9813431.

Bodén S, Harbs J, Sundkvist A, et al., Plasma concentrations of gut hormones acyl ghrelin and Peptide YY and subsequent risk of colorectal cancer and molecular tumor subtypes. Cancer Prev Res (Phila). 2022:CAPR-22-0325. doi: 10.1158/1940-6207.CAPR-22-0325.

Sitohy B, El-Salhy M. Colonic endocrine cells in rats with chemically induced colon carcinoma. Histol Histopathol. 2001;16(3):833-8. doi: 10.14670/HH-16.833.